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Abstract  
BACKGROUND: Nutritional deficits are almost universal in Low-Birth Weight babies. Zinc is 
essential for normal infant growth and its supplementation assists growth probably through insulin-
like growth factor-1. 
AIM: This double-blind randomized-controlled trial aimed at evaluating the role of zinc in catch-up 
growth of low-birth-weight infants and investigating its proposed mediator. 
MATERIAL AND METHODS: The study was conducted in Ain Shams University Maternity 
Hospital. Two hundred low-birth-weight neonates were simply randomized to either oral zinc 
therapy or placebo. Anthropometric measurements were recorded at birth, 3, 6, and 12 months; 
including weight, recumbent length, head, waist, chest, and mid-upper arm circumferences, and 
triceps and sub-scapular skin fold thickness.  
RESULTS: We found that initial and 3-months measurements, except weight, were comparable in 
the 2 groups. All measurements at 6- and 12-months, except sub-scapular skin-fold-thickness, were 
significantly higher in zinc group than placebo. Catch-up growth, at 12-months, was significant in 
zinc group and was significantly higher in appropriate-for-gestational-age vs. small-for-gestational-
age, in preterm vs. term, and in male vs. female infants. The median 6-months insulin-like growth 
factor-1 levels were significantly higher in zinc group. 
CONCLUSION: We conclude that early start of oral zinc supplementation in low-birth-weight 
neonates assists catch-up growth, probably through rise of insulin-like growth factor-1. 
 
 
 
 
 
Introduction 
 
 Low birth weight (LBW) has been defined by 
the World Health Organization (WHO) as weight at 
birth less than 2,500 grams, irrespective to gestational 
age. Its prevalence is higher in developing than 
developed countries [1]. This condition can be due to 
premature birth and/or intrauterine growth restriction 
[2]. 
Nutritional deficits, including micronutrients, 
are almost universal in LBW babies; making them a 
main target for early intervention [3]. Being an integral 
part of more than 100 enzyme systems in human 
body, zinc is essential for normal infant growth and 
development and its deficiency contributes greatly to 
impaired growth [4]. This growth-enhancing action is 
strongly assumed to be mediated by insulin-like 
growth factor (IGF)-1 [5]. 
So, the aim of this trial was to evaluate the 
growth promoting effect of zinc supplementation in 
LBW neonates, and to clarify its relation to the main 
growth hormone mediator, IGF-1. 
 
 
Patients and Methods 
 
This double-blind randomized placebo-
controlled trial; neither the main investigators nor the 
neonates’ parents knew whether the subject was 
receiving drug or placebo, was conducted over the 
period from October 2010 through May, 2012. All 
LBW neonates, whether term or preterm, appropriate 
for gestational age (AGA) or small for gestational age 
(SGA), were eligible. Exclusion criteria included: 
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delayed establishment of enteral feedings, birth 
weight <1500 g, gestational age <28 weeks, 
congenital malformations, chromosomal aberrations 
or evidence of considerable illness. The study was 
approved by the Local Ethical and Research 
Committee; registered approval number is 09202. 
Written consents were taken from parents.  
The study comprised 200 LBW neonates 
whom were randomized; by simple randomization, 
into two groups: Zinc group; including neonates who 
received oral zinc therapy at a dose of 10 mg/day, and 
Placebo group. Randomization tables were kept with 
an independent investigator and were only revealed at 
the time of final statistical analysis. The drug/placebo 
containers were obtained, labeled and numbered by 
the same independent investigator.  
 
Oral therapy (drug or placebo) 
Bottles used for oral therapy, either zinc 
sulfate or placebo, were of the same shape and size. 
The concentration of oral zinc solution was 2 % (20 
mg/ml). To supplement 10mg/day, each infant 
received ½ ml/day. Equal volumes of placebo (distilled 
water) were used for placebo group. The bottles were 
numbered serially by the independent investigator and 
the codes were kept confidential until the study was 
finished. Therapy started with the start of oral feeds 
and lasted for 6 months. 
Anthropometric measurements were recorded 
at birth and then 3-monthly, including weight, length, 
head circumference, waist, chest and mid-upper arm 
circumferences, and triceps and sub-scapular skin 
fold thickness. All measurements were taken on the 
right side and were based on the Anthropometry 
Procedures Manual provided by the US Center for 
Disease Control (CDC) [6].  
 
Laboratory Methods 
Venous blood samples were withdrawn from 
all recruited neonates: initially – within first 3 days 
after birth – for baseline serum zinc measurement, 
and at the 6
th
 months for IGF-1 measurement. 
Samples were centrifuged and sera were stored at -
70
o
C until analysis. Serum zinc was measured using 
Quimica Ckininca Aplicada S.A kit for colorimetric in 
vitro zinc measurement. Serum IGF-1 was measured 
using DIA (IGF1-EASIA).  
Statistical analysis was performed using 
Statistical Package for Social Sciences (SPSS) 
version 16.0. Data for the two independent groups 
were compared using independent student’s t-test and 
the mean difference [MD] with its 95% confidence 
interval [95% CI] (for parametric variables), Mann-
Whitney’s U-test (for non-parametric variables) and 
chi-squared test as well as the relative risk [RR] and 
its 95% CI (for categorical variables). The number 
needed to treat (NNT) was calculated as the 
reciprocal for the absolute risk reduction (ARR). The 
cutoff values for the tenth percentiles of weight, height 
and HC were set according to the CDC charts for 
growth of infants. The significance level was set at 
0.05. 
 
  
Results 
 
Two hundred neonates were recruited; 121 
(60.5%) males and 79 (39.5%) females, 48 (24%) 
term and 152 (76%) preterm, with a mean gestational 
age of 35.08 ± 1.93 (32 – 40) weeks and a mean birth 
weight of 1966.29 ± 307.61 (1500 – 2490) grams. One 
hundred and twenty nine (64.5%) neonates were 
appropriate for gestational age (AGA), while 71 
(35.5%) were small for gestational age (SGA).  
The median initial serum zinc concentration in 
studied neonates was 111.35 g/dl (31 – 554 g/dl; 
IQR 83.3 – 145.5 g/dl). 
Zinc group included 108 neonates and 
Placebo group included 92 neonates. The study 
course and overall drop-out rate [29/200 (14.5%)] are 
presented in a flow diagram. 
 
Figure 1: Flow-Diagram showing Study Course. 
 
Neonates of both groups were non-
significantly different regarding gender distribution 
(62/108 males and 46/108 females in Zinc group vs. 
59/92 males and 33/92 females in Placebo group; p = 
0.332), gestational age (34.95 ± 1.79 vs. 35.28 ± 2.13 
wk, respectively; p = 0.237), birth weight (1944.63 ± 
307.25 vs. 1991.73 ± 307.76 gm, respectively; p = 
0.282), and distribution of AGA and SGA cases 
(69/108 AGA and 39/108 SGA vs. 60/92 AGA and 
32/92 SGA, respectively; p = 0.845).  
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Initial anthropometric measurements were 
also non-significantly different between the 2 groups 
(p >0.05 for all parameters).  
Median (IQR) initial serum zinc levels were 
non-significantly different between the 2 groups 
[114.05 (87.15–144.95) vs. 107.15 (73.38–154.4), 
respectively; p = 0.225]. 
At 3-month-visit, weight was the only 
measurement that significantly increased in Zinc 
group compared to Placebo group with mean values 
of 3964.14 ± 947.23 vs. 3665.69 ± 888.63 gm, 
respectively (p = 0.029; MD = 298.44, 95% CI = 30.7 
to 566.2).  
 
Figure 2: Stacked column showing significantly higher weight in zinc 
than placebo neonates at 3-month-visit. 
 
The percentage of SGA infants who had their 
weight values above 10
th
 percentile for age was not 
statistically different between the 2 groups (10 vs. 8%, 
respectively; p = 0.6, RR = 1.24, 95% CI = 0.49 to 
3.12, NNT = 51). 
Table 1: Comparison of zinc and placebo neonates regarding 
6-months anthropometric measurements. 
 
Group I 
[Zinc Group] 
(n=96) 
Group II 
[Placebo Group] 
(n=83) 
P* 
MD 
(95% CI) 
Weight (9m) 
Min-Max 
Mean ± SD 
4800 – 8800 
6867.71 ± 1247.4 
4300 – 8800 
6350.6 ± 1134.9 
0.006 
S 
427.27 
(123.44 to 
731.11) 
Length (cm) 
Min-Max 
Mean ± SD 
 
51.5 – 73 
63.14 ± 3.93 
52.5 – 72.5 
61.93 ± 3.49 
0.033 
S 
1.2 
(0.1 to 2.3) 
HC (cm) 
Min-Max 
Mean ± SD 
36.3 – 45.8 
41.16 ± 2.17 
34 – 47 
40.35 ± 2.16 
0.013 
S 
0.81 
(0.17 to 1.45) 
Waist Circumference (cm) 
Min-Max 
Mean ± SD 
31.5 – 45 
38.61 ± 3.11 
32 – 43.5 
37.73 ± 2.43 
0.04 
S 
0.87 
(0.04 to 1.7) 
Chest Circumference (cm) 
Min-Max 
Mean ± SD 
35 – 48.5 
41.54 ± 3.04 
32.5 – 46 
40.59 ± 2.74 
0.031 
S 
0.95 
(0.09 to 1.8) 
MAC (cm) 
Min-Max 
Mean ± SD 
8.9 – 17.4 
13.71 ± 1.84 
9 – 17 
13.07 ± 1.71 
0.018 
S 
0.64 
(0.11 to 1.16) 
Triceps SFT (mm) 
Min-Max 
Mean ± SD 
6 – 11 
9.79 ± 1.41 
5 – 11 
9.29 ± 1.49 
0.025 
S 
0.49 
(0.06 to 0.92) 
Subscapular SFT (mm) 
Min-Max 
Mean ± SD 
4.5 – 8.5 
8.12 ± 0.74 
4.5 – 8.5 
8 ± 0.86 
0.316 
NS 
0.12 
(-0.12 to 
0.35) 
* Analysis using Independent Student’s t-Test. MAC= Mid-arm circumference, SFT= Skin 
fold thickness; MD (95% CI) mean difference and its 95% confidence interval; S= 
significant, HS= highly significant, NS= non-significant. 
 
At 6-month-visit, all anthropometric 
measurements, except subscapular skin fold 
thickness, were significantly higher in Zinc group 
compared to Placebo group. 
 
Figure 3: Bar chart showing that percentage of infants above 10
th
 
percentile for weight and length was significantly higher in zinc than 
placebo groups at 6-months, but not for head circumference. 
 
At that time, the proportions of SGA infants 
who showed catch-up growth (i.e. had their weight 
and length values above 10
th
 percentile for age) were 
significantly higher in Zinc than Placebo groups; for 
weight (49 vs. 29%, respectively; p = 0.006, RR = 
1.69, 95% CI = 1.14 to 2.51, NNT = 5) and for length 
(45 vs. 25%, respectively; p = 0.007, RR = 1.77, 95% 
CI= 1.15 to 2.72, NNT = 5). For head circumference, 
higher percentage of SGA infants passed the 10
th
 
percentile in Zinc than Placebo groups, but this was 
statistically non-significant (40 vs. 27%, respectively; 
p>0.05). 
The median IGF-1 levels measured at 6 
months were significantly higher in Zinc compared to 
Placebo groups [median (IQR): 90 (51.7–113.8) vs. 74 
(46–101) ng/ml), respectively; p = 0.023]. However, 
IGF-1 levels did not show significant correlation with 
any of the anthropometric measurements in the two 
groups [r = 0.13, p = 0.2 for weight, r = 0.02, p = 0.8 
for length, and r = 0.03, p = 0.7 for head 
circumference, in Zinc group].  
At 12-month-visit, again, all anthropometric 
measurements, except subscapular skin fold 
thickness, were significantly higher in Zinc group.  
Table 2: Comparison of zinc and placebo neonates regarding 
12-months anthropometric measurements. 
 
Group I 
[Zinc Group] 
(n=92) 
Group II 
[Placebo Group] 
(n=78) 
P* 
MD 
(95% CI) 
Weight (gm) 
Min-Max 
Mean ± SD 
5650 – 11650 
8888.9 ± 1369.5 
4900 – 11650 
8134.8 ± 1377.9 
<0.001 
HS 
752.2 
(336.3 to 1168.03) 
Length (cm) 
Min-Max 
Mean ± SD 
61.9 – 81.9 
73.17 ± 4.12 
61 – 80 
70.46 ± 3.7 
<0.001 
HS 
2.7 
(1.5 to 3.9) 
HC (cm) 
Min-Max 
Mean ± SD 
38.5 – 49.5 
44.92 ± 2.49 
35 – 52 
44.63 ± 2.71 
0.001 
S 
1.3 
(0.49 to 2.07) 
Waist Circumference (cm) 
Min-Max 
Mean ± SD 
32 – 51 
41.74 ± 3.32 
35 – 48.5 
40.78 ± 2.85 
0.046 
S 
0.96 
(0.02 to 1.9) 
Chest Circumference (cm) 
Min-Max 
Mean ± SD 
35.5 – 51.5 
44.13 ± 3.37 
39 – 50.5 
42.83 ± 3.99 
0.022 
S 
1.31 
(0.19 to 2.42) 
MAC (cm) 
Range 
Mean ± SD 
11.5 – 21 
16.18 ± 2.21 
11 – 20.5 
15.27 ± 1.94 
0.005 
S 
0.91 
(0.27 to 1.54) 
Triceps SFT (mm) 
Min-Max 
Mean ± SD 
9.5 – 13 
12.78 ± 0.59 
9 – 13 
12.46 ± 0.94 
0.006 
S 
0.33 
(0.09 to 0.56) 
Subscapular SFT (mm) 
Min-Max 
Mean ± SD 
 
7 – 9 
8.95 ± 0.26 
7.5 – 9 
8.96 ± 0.21 
0.881 
NS 
-0.01 
(-0.08 to 0.07) 
* Analysis using Independent Student’s t-Test. MAC= Mid-arm circumference, SFT= Skin 
fold thickness; MD (95% CI)= mean difference and its 95% confidence interval; S= 
significant, HS= highly significant, NS= non-significant. 
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Figure 4: Stacked column showing significantly higher weight in zinc 
than placebo neonates at 12-month-visit. 
 
At that time, the proportions of SGA infants 
who had their head circumference – as well as weight 
and length – values above 10
th
 percentile for age were 
significantly higher in Zinc group; for head 
circumference (58 vs. 39%, respectively; p = 0.011, 
RR = 1.5, 95% CI = 1.08 to 2.07, NNT = 5), for weight 
(56 vs. 31%, respectively; p = 0.001, RR = 1.79, 95% 
CI = 1.23 to 2.59, NNT = 4) and for length (65 vs. 
39%, respectively; p = 0.001, RR = 1.77, 95% CI = 
1.22 to 2.27, NNT = 4). 
 
Figure 5: Curve plot showing that catch-up of weight was obvious in 
group I (Zinc Group) infants compared to group II (Placebo Group) 
from 6
th
 month (A), catch-up of length was even earlier at the 3
rd
 
month (B), and catch-up for HC was only observed by the 12
th
 
month (C). 
 
Upon comparing SGA to AGA infants – within 
Zinc group – as regards increment of the 3 basic 
anthropometric measurements at 12-month-visit, 
length was the only parameter that significantly 
increased in SGA infants (72.25 ± 4.69 vs. 69.89 ± 
3.65 cm, respectively; p = 0.033, MD = 2.4, 95% CI = 
0.19 to 4.5). 
In the same regard, length was the only 
parameter that showed catch-up in a significantly 
larger proportion of SGA infants out of Zinc group 
compared to Placebo (57 vs. 27%, respectively; p = 
0.017, RR = 2.09, 95% CI = 1.08 to 4.03, NNT = 3). 
At 12-month-visit, preterm infants of Zinc 
group showed significant increase of weight (8840.6 ± 
1391.3 vs. 8016.4 ± 1399.6 gm, respectively; p = 
0.013, MD = 824.2, 95% CI = 325.1 to 1323.4), highly 
significant increase in length (72.8 ± 4.1 vs. 70.1 ± 3.6 
cm, respectively; p < 0.001, MD = 2.7, 95% CI = 1.3 to 
4.1), and significant increase in head circumference 
(44.5 ± 2.5 vs. 43.2 ± 2.7 cm, respectively; p = 0.006, 
MD = 1.3, 95% CI = 0.4 to 2.2). 
Zinc-supplemented term infants, however, 
showed improved length and head circumference 
values compared to placebo infants (p = 0.013 and 
0.04, respectively), but both groups were comparable 
for weight increment (p = 0.114). 
Male infants of Zinc group had their weight, 
length and HC values, at the 12-month-visit, 
significantly higher than those of Placebo group (p < 
0.001 for weight and length, p = 0.002 for HC). On the 
other hand, female infants were comparable between 
the 2 groups regarding all measurements (p > 0.05).  
Importantly, none of our Zinc-supplemented 
infants suffered any of the known side effects of zinc 
such as vomiting, diarrhea, abdominal cramps, or loss 
of appetite.  
 
 
Discussion 
 
Many studies concerned with the effects of 
Zinc supplementation on growth during fetal and early 
postnatal life were done. Our study focused on the 
growth promoting effect of high-dose zinc 
supplementation over a six months period, starting 
from day 1 of enteral feeding in LBW neonates, in 
comparison to placebo. Initial serum zinc levels 
measured in our patients were almost similar between 
the 2 groups. This supported the hypothesis that 
effects of zinc supplementation on growth, if any, are 
clearly dependant on the dose regimen not on body 
reserve.  
The adequate intake (AI) for zinc is 2mg/day 
for both males and females [7], while its 
recommended daily allowance (RDA) in 0-6 months 
infants is 5-10 mg/day [8]. 
The side effects of zinc overdose are very 
rare and none were reported with doses <25 mg/day 
[8] and they include vomiting, diarrhea, abdominal 
cramps, loss of appetite, and manifestations of copper 
and iron deficiency [9]. None of our babies developed 
any of these known side effects. In addition, the same 
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dose as ours was used for one week in neonates with 
idiopathic hyperbilirubinemia in an Indian study by 
Kumar et al. (2014), and they reported no side effects 
[10]. 
Many studies and systematic reviews of trials 
have reported improved weight gain and linear growth 
in LBW infants supplemented with Zinc in different 
dosage regimens and for different durations [5, 11-
13]. Regarding head circumference, significant 
increment was also shown following 6-months-period 
of 5mg/day supplementation [14]. Even when 
supplemented to 4-17 months old infants, zinc 
conferred a beneficial enhancement of head growth 
[15].  
So, it could be now considered as a fact that 
preventive zinc supplementation in populations at risk 
of zinc deficiency increases linear growth and weight 
gain among infants and young children [16]. 
On the other hand, a double-blind placebo-
controlled trial done on 3 to 9 months old infants with 
non-organic failure to thrive showed no growth 
promoting effect of zinc being supplemented for 12 
weeks [17]. This could be explained by other nutrient 
deficiencies which can interfere with the growth 
promoting effect of zinc [18]. In another study, the 
research workers supplemented 128 SGA infants with 
oral zinc for 6 months and reported no effect on their 
growth [19]; this could be explained by their use of low 
doses of zinc. Moreover, supplementation of low 
doses, such as 3 mg/day did not improve growth 
despite increasing serum zinc levels in SGA infants 
[20]. 
The finding of better length increment in SGA 
vs. AGA infants was also reported in a Chilean study 
[21] and our finding of their poorer weight gain was, 
again, similar to some earlier studies [22]. This result 
is also supported by the well-recognized preferential 
action of zinc on cartilage and bone growth [23, 24] 
and by the report of a recent meta-analysis of 24 
studies concluding that benefits from zinc 
supplementation are mainly on linear growth [25].  
Rapid weight gain in infants is associated with 
higher circulating IGF-1 [26]. The relation between 
IGF-1 and zinc was suggested many years ago by 
Ninh et al. (1996) and recently by Alves (2012) who 
reported significantly increased IGF-1 plasma levels 
after 3 months of 5mg daily supplement of zinc in 6-9 
years old children [18, 27]. 
In an Egyptian study, significant elevation of 
IGF-1 correlated with elevation of serum zinc levels 
and with increased height of 50 pre-pubertal short 
children following 3 months of oral zinc 
supplementation [28]. Adding to the same fact, some 
studies reported decreased IGF-1 levels in zinc 
deficient patients [29, 30].  
While our zinc-supplemented males, rather 
than females, had significant growth enhancement, 
some studies reported better linear growth in female 
more than male LBW infants [11, 12].  
In summary, the present results support the 
reports of positive growth promoting effect induced by 
zinc supplementation in LBW neonates and its 
association with elevated IGF-1 which is strongly 
suggested to mediate the catch-up growth induced by 
zinc. This study is unique in the earliest 
supplementation of the highest RDA for zinc. 
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